ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis
USA - NASDAQ:ADMA - US0008991046 - Common Stock
15.69 USD
+0.27 (+1.75%)
15.75 USD
+0.06 (+0.38%)
Overall ADMA gets a fundamental rating of 6 out of 10. We evaluated ADMA against 533 industry peers in the Biotechnology industry. ADMA has an excellent financial health rating, but there are some minor concerns on its profitability. ADMA is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make ADMA a good candidate for value and growth investing.
1. Profitability
1.1 Basic Checks
In the past year ADMA was profitable.
ADMA had a positive operating cash flow in the past year.
ADMA had negative earnings in 4 of the past 5 years.
In multiple years ADMA reported negative operating cash flow during the last 5 years.
1.2 Ratios
ADMA has a better Return On Assets (37.42%) than 98.87% of its industry peers.
ADMA has a Return On Equity of 52.45%. This is amongst the best in the industry. ADMA outperforms 98.50% of its industry peers.
With an excellent Return On Invested Capital value of 25.43%, ADMA belongs to the best of the industry, outperforming 98.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 37.42% | ||
| ROE | 52.45% | ||
| ROIC | 25.43% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ADMA has a better Profit Margin (44.06%) than 98.31% of its industry peers.
Looking at the Operating Margin, with a value of 32.82%, ADMA belongs to the top of the industry, outperforming 97.00% of the companies in the same industry.
ADMA's Gross Margin of 53.00% is fine compared to the rest of the industry. ADMA outperforms 75.98% of its industry peers.
In the last couple of years the Gross Margin of ADMA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.82% | ||
| PM (TTM) | 44.06% | ||
| GM | 53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ADMA is creating value.
Compared to 1 year ago, ADMA has more shares outstanding
The number of shares outstanding for ADMA has been increased compared to 5 years ago.
Compared to 1 year ago, ADMA has an improved debt to assets ratio.
2.2 Solvency
ADMA has an Altman-Z score of 15.88. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ADMA (15.88) is better than 88.37% of its industry peers.
The Debt to FCF ratio of ADMA is 1.12, which is an excellent value as it means it would take ADMA, only 1.12 years of fcf income to pay off all of its debts.
ADMA's Debt to FCF ratio of 1.12 is amongst the best of the industry. ADMA outperforms 93.62% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that ADMA is not too dependend on debt financing.
ADMA has a Debt to Equity ratio of 0.18. This is in the lower half of the industry: ADMA underperforms 66.42% of its industry peers.
Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 1.12 | ||
| Altman-Z | 15.88 |
ROIC/WACC2.9
WACC8.76%
2.3 Liquidity
A Current Ratio of 5.33 indicates that ADMA has no problem at all paying its short term obligations.
ADMA's Current ratio of 5.33 is in line compared to the rest of the industry. ADMA outperforms 58.16% of its industry peers.
A Quick Ratio of 2.78 indicates that ADMA has no problem at all paying its short term obligations.
ADMA has a Quick ratio of 2.78. This is in the lower half of the industry: ADMA underperforms 63.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.33 | ||
| Quick Ratio | 2.78 |
3. Growth
3.1 Past
ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.86%, which is quite impressive.
Looking at the last year, ADMA shows a very strong growth in Revenue. The Revenue has grown by 65.15%.
ADMA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 70.84% yearly.
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)65.15%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
3.2 Future
ADMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.01% yearly.
ADMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.94% yearly.
EPS Next Y21.04%
EPS Next 2Y37.55%
EPS Next 3Y35.8%
EPS Next 5Y32.01%
Revenue Next Year19.81%
Revenue Next 2Y22.86%
Revenue Next 3Y24.53%
Revenue Next 5Y20.94%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 29.06, ADMA can be considered very expensive at the moment.
92.12% of the companies in the same industry are more expensive than ADMA, based on the Price/Earnings ratio.
ADMA is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 25.51, which is the current average of the S&P500 Index.
ADMA is valuated correctly with a Price/Forward Earnings ratio of 16.58.
Based on the Price/Forward Earnings ratio, ADMA is valued cheaper than 94.18% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.98, ADMA is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.06 | ||
| Fwd PE | 16.58 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.06% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ADMA is valued cheaply inside the industry as 91.93% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 57.06 | ||
| EV/EBITDA | 22.79 |
4.3 Compensation for Growth
ADMA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ADMA may justify a higher PE ratio.
A more expensive valuation may be justified as ADMA's earnings are expected to grow with 35.80% in the coming years.
PEG (NY)1.38
PEG (5Y)N/A
EPS Next 2Y37.55%
EPS Next 3Y35.8%
5. Dividend
5.1 Amount
No dividends for ADMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
15.69
+0.27 (+1.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners89.29%
Inst Owner Change5.87%
Ins Owners2.35%
Ins Owner Change-1.53%
Market Cap3.74B
Revenue(TTM)426.45M
Net Income(TTM)208.93M
Analysts84
Price Target27.8 (77.18%)
Short Float %7.27%
Short Ratio4.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.56%
Min EPS beat(2)-31.17%
Max EPS beat(2)-1.96%
EPS beat(4)1
Avg EPS beat(4)-7.13%
Min EPS beat(4)-31.17%
Max EPS beat(4)13.12%
EPS beat(8)4
Avg EPS beat(8)-13.7%
EPS beat(12)6
Avg EPS beat(12)-7.65%
EPS beat(16)9
Avg EPS beat(16)-4.75%
Revenue beat(2)0
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)-2.51%
Revenue beat(4)2
Avg Revenue beat(4)1.84%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)10.99%
Revenue beat(8)6
Avg Revenue beat(8)4.93%
Revenue beat(12)10
Avg Revenue beat(12)6.13%
Revenue beat(16)14
Avg Revenue beat(16)6.66%
PT rev (1m)-6.23%
PT rev (3m)-6.23%
EPS NQ rev (1m)-2.17%
EPS NQ rev (3m)-10%
EPS NY rev (1m)4.7%
EPS NY rev (3m)-2.2%
Revenue NQ rev (1m)-0.51%
Revenue NQ rev (3m)0.17%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.06 | ||
| Fwd PE | 16.58 | ||
| P/S | 7.9 | ||
| P/FCF | 57.06 | ||
| P/OCF | 48.81 | ||
| P/B | 9.4 | ||
| P/tB | 9.5 | ||
| EV/EBITDA | 22.79 |
EPS(TTM)0.54
EY3.44%
EPS(NY)0.95
Fwd EY6.03%
FCF(TTM)0.27
FCFY1.75%
OCF(TTM)0.32
OCFY2.05%
SpS1.99
BVpS1.67
TBVpS1.65
PEG (NY)1.38
PEG (5Y)N/A
Graham Number4.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 37.42% | ||
| ROE | 52.45% | ||
| ROCE | 32.19% | ||
| ROIC | 25.43% | ||
| ROICexc | 31.27% | ||
| ROICexgc | 31.6% | ||
| OM | 32.82% | ||
| PM (TTM) | 44.06% | ||
| GM | 53% | ||
| FCFM | 13.84% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score5
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 1.12 | ||
| Debt/EBITDA | 0.45 | ||
| Cap/Depr | 140.25% | ||
| Cap/Sales | 2.34% | ||
| Interest Coverage | 13.21 | ||
| Cash Conversion | 46.9% | ||
| Profit Quality | 31.4% | ||
| Current Ratio | 5.33 | ||
| Quick Ratio | 2.78 | ||
| Altman-Z | 15.88 |
F-Score5
WACC8.76%
ROIC/WACC2.9
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y21.04%
EPS Next 2Y37.55%
EPS Next 3Y35.8%
EPS Next 5Y32.01%
Revenue 1Y (TTM)65.15%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
Revenue Next Year19.81%
Revenue Next 2Y22.86%
Revenue Next 3Y24.53%
Revenue Next 5Y20.94%
EBIT growth 1Y85.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.25%
EBIT Next 3Y41.34%
EBIT Next 5Y36.11%
FCF growth 1Y227.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y285.06%
OCF growth 3YN/A
OCF growth 5YN/A
ADMA BIOLOGICS INC / ADMA FAQ
What is the fundamental rating for ADMA stock?
ChartMill assigns a fundamental rating of 6 / 10 to ADMA.
Can you provide the valuation status for ADMA BIOLOGICS INC?
ChartMill assigns a valuation rating of 7 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Undervalued.
How profitable is ADMA BIOLOGICS INC (ADMA) stock?
ADMA BIOLOGICS INC (ADMA) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ADMA BIOLOGICS INC (ADMA) stock?
The Price/Earnings (PE) ratio for ADMA BIOLOGICS INC (ADMA) is 29.06 and the Price/Book (PB) ratio is 9.4.
Can you provide the financial health for ADMA stock?
The financial health rating of ADMA BIOLOGICS INC (ADMA) is 7 / 10.